Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

"Stigma isn't just a social issue; it's a public health crisis." says Marcus Wilson, Gilead Senior Director, U.S. Public Affairs, HIV Advocacy. "It determines the quality of care that people ...

NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients a ...